Since 2006, three vaccines against infections and disease caused by human papillomavirus
(HPV) became available in Europe—in 2006 a quadrivalent HPV 6/11/16/18 vaccine, in …

Opinion statement In the United States, there are 11,150 cases and 3670 deaths projected
due to invasive cervical cancer for 2007. Approximately 500,000 new cases and 274,000 …

Persistent infection with oncogenic human papillomavirus (HPV) is a necessary cause of
cervical cancer. Moreover, HPV type 16 (and to a lesser degree HPV type 18) is linked with …

Human papilloma virus (HPV) infections, which are common, produce epithelial lesions of
the nongenital and genital skin and mucous membranes. Although most infections are …

The majority of human papillomavirus (HPV) belong to the genus alpha-papillomavirus,
which can be further subdivided into species and then strains. Approximately 200 strains of …

The human papillomavirus (HPV) represents one of the most common sexually transmitted
infections and it has been related to cervical cancer. The HPV vaccines prevent infection …

Human papillomavirus (HPV) related disease remains a major cause of morbidity and
mortality worldwide. Prophylactic vaccines have been recognized as the most effective …

Persistent infection with oncogenic human papillomavirus (HPV) is a necessary causal
factor in the development of cervical cancer. Moreover, HPV, predominately type 16 and to a …

Countries are now challenged by the rapid development of vaccines aimined at the primary
prevention of infections. In the years to come, several vaccines will need to be considered as …

An association between human papillomavirus (HPV) infection and the development of
cervical cancer was initially suggested over 30 years ago, and today there is clear evidence …